T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.07% |
| 2 | Healthcare | 18.73% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.39% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Aurinia Pharmaceuticals
AUPH
$2.19B
| $162K | ﹤0.01% |
21,458
+8,659
| +68% | +$75K |
|
2602
Vaalco Energy
EGY
$619M
| $162K | ﹤0.01% |
36,971
+3,594
| +11% | +$18.4K |
|
2603
UWM Holdings
UWMC
$400M
| $162K | ﹤0.01% |
55,211
+9,066
| +20% | +$33.4K |
|
2604
Xeris Biopharma Holdings
XERS
$1.75B
| $162K | ﹤0.01% |
103,609
+66,975
| +183% | +$111K |
|
2605
Mirion Technologies
MIR
$3.62B
| $161K | ﹤0.01% |
21,492
+8,422
| +64% | +$59.3K |
|
2606
Purple Innovation
PRPL
$10.7M
| $161K | ﹤0.01% |
1,589
+983
| +162% | +$85.4K |
|
2607
Quantum Corp
QMCO
$1.25B
| $159K | ﹤0.01% |
7,320
+1,020
| +16% | +$32.8K |
|
2608
Atea Pharmaceuticals
AVIR
$417M
| $158K | ﹤0.01% |
27,621
+4,540
| +20% | +$34.8K |
|
|
DCH
2609
Dauch Corp
DCH
$1.26B
| $158K | ﹤0.01% |
23,121
+7,510
| +48% | +$67.6K |
|
2610
Perimeter Solutions
PRM
$4.67B
| $158K | ﹤0.01% |
19,709
+8,085
| +70% | +$83.4K |
|
2611
Telos
TLS
$305M
| $156K | ﹤0.01% |
17,530
-5,510
| -24% | -$50.8K |
|
2612
Wave Life Sciences
WVE
$723M
| $156K | ﹤0.01% |
43,080
+14,100
| +49% | +$46.7K |
|
2613
Energy Fuels
UUUU
$2.92B
| $155K | ﹤0.01% |
25,258
+10,141
| +67% | +$64.8K |
|
2614
Corsair Gaming
CRSR
$1.45B
| $154K | ﹤0.01% |
13,542
+2,285
| +20% | +$32.8K |
|
|
GAN
2615
DELISTED
GAN Ltd
GAN
| $153K | ﹤0.01% |
68,600
+33,200
| +94% | +$101K |
|
2616
Alaunos Therapeutics
TCRT
$2.64M
| $153K | ﹤0.01% |
590
-73
| -11% | -$21.2K |
|
2617
The ONE Group
STKS
$52M
| $152K | ﹤0.01% |
22,767
+8,808
| +63% | +$68.1K |
|
|
CNSL
2618
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $152K | ﹤0.01% |
36,403
-17,720
| -33% | -$110K |
|
2619
Cogent Biosciences
COGT
$5.42B
| $151K | ﹤0.01% |
+10,104
| New | +$138K |
|
|
USX
2620
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $151K | ﹤0.01% |
61,000
-2,739,381
| -98% | -$7.76M |
|
2621
Citizens
CIA
$183M
| $149K | ﹤0.01% |
44,500
+5,800
| +15% | +$22K |
|
2622
Golub Capital BDC
GBDC
$3.22B
| $149K | ﹤0.01% |
12,000
| – | – |
|
2623
McEwen Inc
MUX
$1.12B
| $148K | ﹤0.01% |
45,380
+11,100
| +32% | +$38.3K |
|
|
DBD
2624
DELISTED
Diebold Nixdorf Incorporated
DBD
| $147K | ﹤0.01% |
59,893
+5,552
| +10% | +$18.5K |
|
2625
Beam Global
BEEM
$26.3M
| $146K | ﹤0.01% |
11,900
| – | – |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.